BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28423708)

  • 1. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.
    Rabinowicz N; Mangala LS; Brown KR; Checa-Rodriguez C; Castiel A; Moskovich O; Zarfati G; Trakhtenbrot L; Levy-Barda A; Jiang D; Rodriguez-Aguayo C; Pradeep S; van Praag Y; Lopez-Berestein G; David A; Novikov I; Huertas P; Rottapel R; Sood AK; Izraeli S
    Oncotarget; 2017 Apr; 8(16):27380-27392. PubMed ID: 28423708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
    Bhattacharjee V; Zhou Y; Yen TJ
    Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair.
    Ovejero-Sánchez M; González-Sarmiento R; Herrero AB
    Neoplasia; 2021 May; 23(5):515-528. PubMed ID: 33930758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
    Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
    Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) promotes non-homologous end joining and inhibits homologous recombination repair upon DNA damage.
    Tang M; Li Y; Zhang X; Deng T; Zhou Z; Ma W; Songyang Z
    J Biol Chem; 2014 Dec; 289(49):34024-32. PubMed ID: 25294876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
    Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
    Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Xu Z; Li X; Li H; Nie C; Liu W; Li S; Liu Z; Wang W; Wang J
    Oncogene; 2020 Nov; 39(47):7051-7062. PubMed ID: 32989256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
    Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
    Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
    Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
    Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.
    Wu Y; Lee SH; Williamson EA; Reinert BL; Cho JH; Xia F; Jaiswal AS; Srinivasan G; Patel B; Brantley A; Zhou D; Shao L; Pathak R; Hauer-Jensen M; Singh S; Kong K; Wu X; Kim HS; Beissbarth T; Gaedcke J; Burma S; Nickoloff JA; Hromas RA
    PLoS Genet; 2015 Dec; 11(12):e1005675. PubMed ID: 26684013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.